Organon & Co | OGN - Current Assets

Stock Price
13.36
Daily Change
0 0%
Monthly
45.06%
Yearly
51.73%
Q2 Forecast
13.07

Organon & Co reported $4.93B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Celltrion KRW 470.6B 5.07T Dec/2025
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 1.12B 710.47M Mar/2026
Divis Laboratories Ltd INR 98.43B 2.38B Sep/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Kangmei Pharma CNY 7.03B 128.34M Sep/2025
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Organigram Holdings CAD 256.54M 28.35M Dec/2025
Organon & Co USD 4.93B 580M Mar/2026
Ovoca Bio EUR 1.56M 3.39M Jun/2025
Pharma Mar EUR 273.45M 9.96M Mar/2026
Qiagen NV USD 2B 535.87M Dec/2025
Sartorius EUR 1.92B 157.2M Mar/2026
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Tilray USD 729.32M 28.18M Sep/2025
Zealand Pharma A/S 15.67B 950.94M Dec/2025